D
irect oral anticoagulants (DOACs) have enjoyed a rapid adoption in the United States since the initial approval of dabigatran in 2010. By 2014, use of DOACs was similar to the use of warfarin among US patients with atrial fibrillation.
1 Four DOACs are approved in the United States: the thrombin inhibitor dabigatran and the Factor Xa inhibitors rivaroxaban, apixaban, and edoxaban. All 4 are approved for reduction of stroke/systemic embolism in nonvalvular atrial fibrillation (edoxaban only if creatinine clearance is 95 mL/min) and treatment of deep venous thrombosis and pulmonary embolism. Dabigatran, rivaroxaban, and apixaban also have been approved for secondary prevention of deep venous thrombosis and pulmonary embolism, as well as prophylaxis of deep venous thrombosis after joint replacement.
Unlike warfarin, which acts by inhibiting synthesis of vitamin K-dependent clotting factors, the anticoagulant activity of DOACs is related directly to their pharmacokinetic characteristics. Thus, they provide rapid onset of anticoagulant activity, given their times to maximum plasma concentration of 1 to 4 hours, and relatively rapid offset, given their half-lives that are in the range of 5 to 17 hours.
When deciding whether to use a new medication such as the DOACs, a variety of factors need to be considered, including efficacy and safety, as well as other variables such as cost, ease of use, availability, and patient preference. Issues that may impact ease of use and patient preference include the number of daily doses, need for regular laboratory monitoring, dietary restrictions, and patient attitudes regarding risk of bleeding vs risk of stroke. This editorial briefly discusses efficacy of the DOACs compared with conventional anticoagulation and then focuses on the major safety issue with anticoagulation, bleeding in the gastrointestinal tract and other locations.
Efficacy of Direct Oral Anticoagulants
Individual large landmark trials with each of the 4 DOACs compared with warfarin in patients with nonvalvular atrial fibrillation have shown significant benefit 2,3 or a trend to benefit (upper bounds of 95% confidence interval for hazard ratios of 1.03 4 and 1.04 5 ) in the primary outcome of stroke or systemic embolism. A meta-analysis of the 4 trials showed significant relative risk reductions of 19% in stroke/systemic embolism (mainly driven by a large decrease in hemorrhagic stroke) and 10% in mortality, without significant statistical heterogeneity. 6 In contrast, Cochrane meta-analyses found no significant difference in efficacy between DOACs and standard therapy for treatment of deep venous thrombosis or pulmonary embolism. 7, 8 Safety: Bleeding With Anticoagulant Therapy
Vitamin K Antagonists
A meta-analysis of 6 randomized trials comparing vitamin K antagonists with placebo or no treatment for nonvalvular atrial fibrillation showed a significant 2.2-fold increase in major bleeding, 9 with similar relative risk increases in intracranial and extracranial hemorrhage. 10 A meta-analysis of 4 of these trials showed an odds ratio for major gastrointestinal bleeding (GIB) of 3.2 (95% confidence interval, 1.3-7.8), 11 whereas a recent case-control study reported a relative risk of 4.4 with vitamin K antagonists for upper GIB and 4.1 for lower GIB. 12 
Direct Oral Anticoagulants
Given the rapid uptake of DOACs, it is important for us to understand the risk of GIB with DOACs as compared with conventional anticoagulation therapy. In this issue of Clinical Gastroenterology and Hepatology, Miller et al 13 present a systematic review of GIB with DOACs across the major indications for anticoagulation. Their primary meta-analysis showed no suggestion of a difference in major GIB between DOACs and conventional therapy, with an odds ratio of 0.98. However, significant heterogeneity was present, indicating that the variability among the different study results was greater than expected owing to chance alone.
Heterogeneity raises the question of whether aggregating the data into a single pooled statistic provides a meaningful summary of the treatment effect. The treatment effect might vary in different situations (eg, different populations, different indications, different drugs or doses, different comparators). The heterogeneity in the main meta-analysis of 28 trials by Miller et al 13 was not surprising, given that it included comparisons of 4 separate DOACs at different doses in a variety of conditions, and that controls included placebo and aspirin in addition to conventional anticoagulants. Sensitivity analyses can be performed in an attempt to identify potential reasons for heterogeneity, as performed by Miller et al. 13 For example, pooled analyses for each individual DOAC (standard and lower doses combined) showed differing treatment effects: an increase in major GIB with dabigatran and rivaroxaban vs controls but no significant difference with apixaban or edoxaban vs controls.
A review of Figure 2 from Miller et al 13 shows that the majority of data in the meta-analysis were provided by just 4 trials-1 trial for each of the approved DOACs. These landmark trials, in patients with nonvalvular atrial fibrillation, were larger and longer than other trials, each with more than 6000 patients per treatment arm and median exposures of 1.6 to 2.5 years. More careful examination of these high-quality trials, performed in similar populations with similar comparators, may be instructive (Table 1) .
Gastroenterologists naturally focus primarily on GIB. Nevertheless, bleeding episodes from all sources must be considered when assessing the risk-benefit balance of DOACs. Table 1 shows that, overall, major bleeding was not different from warfarin with either dabigatran or rivaroxaban. However, there were relative risk reductions in major bleeding of 30% with apixaban and 20% with edoxaban. A review of Table 1 shows that only approximately one third of major bleeding episodes associated with warfarin were caused by GIB. Furthermore, the annualized rate of major GIB with warfarin in these studies (0.9%-1.2%) was not much greater than the rate of the much more serious intracranial bleeding (0.7%-0.9%). Thus, GIB accounted for a minority of major bleeding episodes and the more devastating outcome of intracranial bleeding occurred nearly as commonly as GIB with warfarin therapy.
Importantly, results of comparisons between DOACs and warfarin varied markedly with the site of bleeding. Major GIB showed relative risk increases of approximately 20% to 50% with 3 of the DOACs and no significant difference with apixaban (Table 1) . In contrast, intracranial bleeding was lower with all 4 of the DOACs as compared with warfarin, with approximately 30% to 60% relative risk reductions. The observation that DOACs have a relatively higher rate of GIB as compared with nongastrointestinal sources such as intracranial hemorrhage is postulated to relate to a direct topical anticoagulant effect of DOACs in the gastrointestinal tract, which is not present with warfarin. 14 As mentioned, apixaban was the one DOAC not showing an increase in major GIB in the randomized trials summarized in Table 1 . A recent observational study provided further support for a difference in the incidence of GIB among DOACs in real-world practice: apixaban was associated with significant 61% and 67% relative risk reductions in GIB as compared with dabigatran and rivaroxaban, respectively. 15 
Conclusions: It Is Not All About the Gastrointestinal Tract
The DOACs have been adopted rapidly into clinical practice, presumably owing at least in part to the lack of requirements for serial laboratory monitoring and dietary restriction and to the potential for greater reduction in stroke/systemic embolism as compared with warfarin in patients with nonvalvular atrial fibrillation. On the other hand, high cost is an important factor that may limit the choice of a DOAC in practice.
Safety is key in decisions regarding anticoagulants, and bleeding is the most important harm that occurs with anticoagulation therapy. Studies have suggested that patients are willing to endure multiple bleeding episodes to reduce the risk of stroke, but there is wide variation among patients. For example, in a study of 152 in-patients with atrial fibrillation, 42% would accept no increase in risk of bleeding to prevent a stroke whereas 15% had no concern about bleeding. 16 The type of bleeding episode also would seem to be important. The sequelae of intracranial hemorrhage are likely to be more frequent and severe than those after GIB.
Based on the meta-analysis of Miller et al 13 and the results of the large landmark studies listed in Table 1 , [2] [3] [4] [5] we can summarize the incidences of major bleeding with standard doses of the DOACs as compared with conventional anticoagulant therapy such as warfarin as follows: (1) overall, major bleeding is higher with dabigatran and rivaroxaban, but is lower with apixaban and edoxaban; (2) major GIB is higher with dabigatran, rivaroxaban, and probably edoxaban, but is not increased with apixaban; and (3) intracranial bleeding is lower with all 4 DOACs. Although the results vary among the individual trials in Table 1 , pooled analyses showed that use of DOACs vs warfarin was associated with a 0.54% absolute increase in major GIB, but a 0.75% absolute decrease in intracranial bleeding over the course of the studies. 6 In conclusion, GIB accounted for only approximately one third of major bleeding episodes in patients with nonvalvular atrial fibrillation on long-term warfarin therapy-and approximately one half in patients on longterm DOACs. Furthermore, the incidence of intracranial bleeding, a more devastating event than GIB, may approach that of major GIB in patients on long-term warfarin but is markedly lower in patients on DOACs. Thus, we cannot have tunnel vision when assessing the safety of anticoagulant therapy. Focusing exclusively on GIB without considering bleeding beyond the gastrointestinal tract provides an incomplete picture and may constitute a disservice to patients requiring long-term anticoagulant therapy. 
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